Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: Mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 6, 2005, Pages 727-734

  Zhang, Tian Tai ^a   Cui, Bing ^a   Dai, De Zai ^a   Tang, Xiao Yun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CPU 86017; Endothelin 1; Inducible nitric oxide synthase; Pulmonary hypertension; Reactive oxygen species

Indexed keywords

4 CHLOROBENZYLTETRAHYDROBERBERINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CPU 86017; ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; MESSENGER RNA; NIFEDIPINE; NITRIC OXIDE; PREPROENDOTHELIN 1; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 4-CHLOROBENZYLTETRAHYDROBERBERINE; ANTIOXIDANT; BERBERINE; CALCIUM CHANNEL L TYPE; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM ANTAGONISM; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; HEART VENTRICLE CONTRACTION; HEMODYNAMICS; HISTOPATHOLOGY; HYPOXIA; INHIBITION KINETICS; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANOXIA; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; HEART RIGHT VENTRICLE HYPERTROPHY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANOXIA; ANTIOXIDANTS; BERBERINE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; ENDOTHELIN-1; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MALONDIALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33644673222     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000184470.58047.79     Document Type: Article

References (28)

1. Benisty JI. Pulmonary hypertension. Circulation. 2002;106:192-194.
2. O'Callaghan D, Gaine SP. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract. 2004;58:69-73.
3. Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med. 2003;9:131-138.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13-24.
5. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can J Physiol Pharmacol. 2003;81:533-541.
6. Tang YQ, Dai DZ, Zhao J, et al. Protective effect of pretreatment with tetrahydroberberine chloride in hypoxic damage in mouse cerebral mitochondria. Chin J Pharmacol Toxicol. 1996;10:31-32.
7. Wang YQ, Shi YP, Dai DZ. The therapeutic effects of CPU 86017 on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats. Drug Dev Res. 2004;63:22-32.
8. Pauvert O, Bonnet S, Rousseau E, et al. Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004;287:577-583.
9. Venuti A, Salani D, Manni V, et al. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J. 2000;14:2277-2283.
10. Dai DZ, Feng Y, Li HT, et al. Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017. Drug Dev Res. 1996;39:138-146.
11. Wang HL, Li SB, Dai DZ. Effects of CPU 86017 on L-type calcium current in single guinea pig hypertrophic ventricular myocytes. J China Pharmaceut Univ. 2004;35:259-262.
12. Dai DZ, He Y, Huang FH, et al. Comparison of inhibitory activity of berberine derivate CPU 86017 and berberine on vascular contraction. J China Pharmaceut Univ. 2000;31:447-450.
13. Pellicelli AM. Cytokines in portopulmonary hypertension. Gut. 2004;53:1721.
14. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
15. Freitas CF, Faro R, Dragosavac D, et al. Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs. J Cardiovasc Pharmacol. 2004;43:106-112.
16. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodeling in a canine PH model of chronic embolic pulmonary hypertension. Eur Respir J. 2000;15:640-648.
17. 2+ entry mechanisms of vascular contraction. Hypertension. 2003;42:818-824.
18. 2+ and calcineurin by NO/PKG in proliferation of vascular smooth muscle cells. Acta Pharmacol Sin. 2005;26:323-328.
19. Mazzocchi G, Rossi GP, Malendowicz LK, et al. Endothelin-1 [1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett. 2000;29:194-198.
20. Piacentini L, Gray M, Honbo NY, et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol. 2000;32:565-576.
21. Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110:1269-1275.
22. Kalinowski L, Malinski T. Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol. 2004;51:459-469.
23. Sham JS. Hypoxic pulmonary vasoconstriction: ups and downs of reactive oxygen species. Circ Res. 2002;18:649-651.
24. Wedgwood S, Black SM. Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. Antioxid Redox Signal. 2003;5:759-769.
25. Goraca A. New views on the role of endothelin. Endocr Regul. 2002;36:161-167.
26. Resta TC, Chicoine LG, Omdahl JL, et al. Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol. 1999;276:699-708.
27. Fleming I, Fisslthaler B, Dimmeler S, et al. phosphorylation of Thr495 regulates Ca2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88:68-75.
28. Murata T, Sato K, Hori M, et al. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem. 2002;277:44085-44092.